Lenvatinib in Anaplastic Thyroid Carcinoma (ATC) in a Tertiary Caner Hospital- a Single Institute Experience
Rakesh Sharma
BOG and OSD, National Board of Examinations, Delhi, India.
P. S. Dattatreya
Department of Medical Oncology, Omega Hospitals, Hyderabad, India.
A. V. S. Suresh *
Department of Medical Oncology, Omega Hospitals, Hyderabad, India.
Ch Mohana Vamsy
Department of Surgical Oncology, Omega Hospitals, Hyderabad, India.
*Author to whom correspondence should be addressed.
Abstract
Anaplastic Thyroid Carcinoma (ATC) is an aggressive rare form of caner with limited treatment options and short survival. In view of initial case reports have shown some good clinical response with lenvatinib, we used the same in our institute. We are presenting a retrospective series of 4 cases between 2018-2021. It showed very promising results with 75% showing clinically meaningful regression of tumor. Hypertension is the most common side effect, which should be aggressively managed. We feel that, lenvatinib remains a safe and effective option to explore in patients with refractory anaplastic thyroid carcinoma.
Keywords: Anaplastic thyroid carcinoma, lenvatinib, India